TNFRSF1A and autoimmune hepatitis: With respect to therapy of inflammatory and autoimmune liver disease, future trials should investigate the therapeutic efficacy of selective TNFR1 antagonists that inhibit liver inflammation while sparing the suppressive functions of Tregs.